Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member SignaturesOpen in a New Window

BEIJING--(BUSINESS WIRE)--Senior management of Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong have commenced legal proceedings in the High Court of the Hong Kong Special Administrative Region to nullify and remove forged documents that were illegally filed with the Hong Kong Companies Registry in respect of Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and with the Industry and Commerce Bureau of Beijing in respect of Sinovac B

 

AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn ConferenceOpen in a New Window

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center and Associate Professor of Surgery at LSU He

 

アスペクト・バイオシステムズが肝組織の開発に向けJSRとの協業を発表Open in a New Window

加ブリティッシュコロンビア州バンクーバー--(BUSINESS WIRE)--(ビジネスワイヤ) -- 最先端のバイオプリンティング技術の商業化に傾注する非公開バイオテクノロジー企業のアスペクト・バイオシステムズは、JSR株式会社と共同でヒト肝組織の開発に向けた新しい協業をスタートすることを発表しました。JSRはエラストマーや半導体、ディスプレイ、およびライフサイエンス分野において最先端の材料やサービスを開発、提供する化学メーカーです。本協業を通じ、アスペクト保有の3DバイオプリンティングプラットフォームLab-on-a-Printer™とJSRの先進的な素材技術を融合させ、血管ネットワークを備えたヒト肝組織を開発していきます。 アスペクト・バイオシステムズの社長兼最高経営責任者(CEO)であるTamer Mohamedは、次のように述べています。「JSRとの協業では、薬物動態予測が可能なヒト肝組織プラットフォームを開発します。この協業を通して、予期せぬ肝毒性という大きな問題に取り組み、疾患モデルを実現させ、新薬開発の促進に貢献します。当社バイオプリンティング技術を最大限に活用し、J

 

Resumen: La solución de cumplimiento online (COMPLi™) de Scientist.com gana prestigioso premio CPhl PharmaOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com ha anunciado que su solución de cumplimiento online COMPLi™ ha sido la ganadora en la categoría Procesos normativos y cumplimiento de los prestigiosos Premios CPhl Pharma 2018 entregados en Madrid (España) el 9 de octubre. COMPLi™ es la primera solución de su clase que permite a las empresas farmacéuticas y biotecnológicas externalizar con confianza servicios regulados, como adquisición de muestras biológicas humanas, evidencias del mundo real secundari

 

Scientist.com’s Online Compliance Solution (COMPLi™) wint prestigieuze CPhl Pharma AwardOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com is verheugd om aan te kondigen dat haar online compliance oplossing COMPLi™ is bekroond tot de winnaar van de prestigieuze Regulatory Procedures and Compliance award tijdens de 2018 CPhl Pharma Awards gehouden in Madrid, Spanje op 9 oktober 2018. COMPLi™ is een eerste oplossing in zijn soort die farmaceutische en biotech bedrijven in staat stelt om met vertrouwen gereguleerde diensten zoals de aankoop van menselijke biologische monsters (HBS), secundair

 

Lösung von Scientist.com für Online-Compliance (COMPLi™) gewinnt prestigeträchtigen CPhI Pharma AwardOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com freut sich bekanntgeben zu dürfen, dass die Lösung des Unternehmens für Online-Compliance COMPLi™ bei den CPhI Pharma Awards 2018, die am 9. Oktober 2018 in Madrid, Spanien, vergeben wurden, als Gewinner des prestigeträchtigen Preises für Regulatorische Angelegenheiten und Compliance anerkannt wurde. COMPLi™ ist die erste Lösung ihrer Art, mit der Unternehmen im Bereich Pharma und Biotech regulierte Dienste wie die Gewinnung biologischer Proben humanen

 

La solution de conformité en ligne (COMPLi™) de Scientist.com remporte le prestigieux prix CPhl PharmaOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com a le plaisir d’annoncer que sa solution de conformité en ligne, COMPLi™, a été sélectionnée comme lauréate du prestigieux prix Procédures réglementaires et conformité au concours  CPhl Pharma Awards 2018 organisé à Madrid, en Espagne, le 9 octobre 2018. COMPLi™ est une solution unique en son genre, qui permet aux sociétés pharmaceutiques et biotechnologiques d’externaliser en toute confiance des services réglementés tels que l’acquisition d’échantillons

 

Riassunto: La soluzione per la conformità online di Scientist.com (COMPLi™) viene riconosciuta alla prestigiosa premiazione CPhl Pharma AwardOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Scientist.com è lieta di annunciare che la sua soluzione per la conformità online COMPLi™ ha vinto il prestigioso premio Procedure di regolamentazione e conformità alla Premiazione CPhl Pharma del 2018 (2018 CPhl Pharma Awards) tenuta a Madrid, Spagna, il 9 ottobre 2018. COMPLi™ è la primissima soluzione che permette alle imprese operanti nei settori farmaceutico e biotecnologico di servirsi in tutta sicurezza di servizi in outsourcing regolamentati come quelli per l

 

Study Finds Only 59 Percent of Young Adults Undergoing Surgery Are Fluid ResponsiveOpen in a New Window

NEWTON, Mass.--(BUSINESS WIRE)--Trial results leveraging Cheetah Medical technology were presented today at the American Society of Anesthesiologists annual meeting in San Francisco.

 

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $

 

Pulse Biosciences Grants Equity Incentive Awards to New EmployeesOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ: PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018. The 2017

 

Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018Open in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

 

IQVIA to Announce Third-Quarter 2018 Results on October 22, 2018Open in a New Window

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter 2018 financial results before the market opens on Monday, October 22, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. Interested parties are invited to

 

Enzo Biochem Reports Fourth Quarter and Fiscal 2018 ResultsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, today reported results for the fourth quarter and fiscal year ended July 31, 2018, in addition to announcing New York State department of Health’s approval of additional assays for new women’s health infectious disease panel continuing to drive focus in development of lower cost products, platforms and services for the clinical laboratory market. Recent Developments Progress in molecular

 

QIAGEN’s Next-Generation QIAstat-Dx System Delivers Fast, Cost-Effective Diagnosis of Gastrointestinal SyndromesOpen in a New Window

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--$QGEN--QIAGEN’s next-generation QIAstat-Dx system delivers fast, cost-effective diagnosis of gastrointestinal syndromes

 

QIAGENs QIAstat-Dx-System liefert die nächste Generation schneller, kosteneffizienter Diagnosen gastrointestinaler SyndromeOpen in a New Window

HILDEN, Deutschland & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die europäische Markteinführung der nächsten Generation des QIAstat-Dx®-Panels für eine einstufige, voll integrierte molekulare Analyse von gastrointestinalen Syndromen bekannt. Das Multiplex-Magen-Darm-Panel, das von QIAGEN um eine umfassende Abdeckung von Viren erweitert wurde, erkennt die 24 häufigsten viralen, bakteriellen und parasitischen Erreger von Magen-Darm-Infekti

 

Certara’s Synchrogenix Division Collaborates with Hedera Hashgraph to Offer Data Flow and Transparent Collaboration Solutions for the Life Sciences IndustryOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it has formed a strategic collaboration with Hedera Hashgraph.

 

Riassunto: GHX sarà tra gli espositori al MEDICA 2018 – Forum globale per il settore sanitarioOpen in a New Window

DÜSSELDORF, Germania--(BUSINESS WIRE)--Global Healthcare Exchange (GHX), un leader nello sviluppo di soluzioni cloud per la gestione della supply chain nel settore sanitario, parteciperà al più importante salone internazionale dell’industria medica, MEDICA 2018, che si terrà a Düsseldorf, Germania, dal 12 al 15 novembre 2018. GHX offre una gamma completa di soluzioni intelligenti per la supply chain e l’e-commerce progettate specificamente per il complesso mondo dell’assistenza sanitaria. La su

 

Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in CanadaOpen in a New Window

NÎMES, France--(BUSINESS WIRE)--Regulatory News: Advicenne (Paris:ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial for the treatment of distal Renal Tubular Acidosis (dRTA) in Canada from Health Canada’s Office of Clinical Trial. “After clearance obtained in September from the

 

Advicenne reçoit l’autorisation de Santé Canada pour étendre son essai clinique pivot de phase III avec ADV7103 au CanadaOpen in a New Window

NÎMES, France--(BUSINESS WIRE)--Advicenne reçoit l’autorisation de Santé Canada pour étendre son essai clinique pivot de phase III avec ADV7103 au Canada.

 

Global Drug of Abuse Testing Market (By Product Type, Sample/Test Type, End Users / Setting Type, Region), Regulatory Status, 20 Company Profiles - Forecast to 2024 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Drug of Abuse Testing Market (By Product Type, Sample/Test Type, End Users / Setting Type, Region), Regulatory Status, 20 Company Profile - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering. The global drug of abuse testing market is projected to cross US$ 5 Billion by 2024. Drugs of abuse testing involves detection of one or more illegal and/or prescribed substances in the urine, blood, saliva, hair, or sweat. The use of illicit d

 

PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCsOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare skin conditions at their source, today presented updated clinical data from two Phase 2 studies of patidegib topical gel in a poster session at NORD’s Rare Diseases and Orphan Products Breakthrough Summit 2018 in Washington, D.C. Results of the studies showed clinical clearance and prevention of basal cell carcinoma (BCC) tumors after 6 months of treatment with patidegib topic

 

Resumen: GHX expondrá en MEDICA 2018 – el foro mundial de la atención sanitariaOpen in a New Window

DÜSSELDORF, Alemania--(BUSINESS WIRE)--Global Healthcare Exchange (GHX), líder en soluciones de gestión de la cadena de suministro de la atención sanitaria basada en la nube, expondrá en la principal feria internacional del sector médico, MEDICA 2018, en Düsseldorf (Alemania) del 12 al 15 de noviembre de 2018. GHX ofrece una completa gama de soluciones de la cadena de suministro y comercio electrónico inteligentes diseñados específicamente para el complejo mundo de la atención sanitaria. La tec

 

Samenvatting: GHX Exposeert op MEDICA 2018 – Het Wereld Forum voor GezondheidszorgOpen in a New Window

DÜSSELDORF--(BUSINESS WIRE)--Global Healthcare Exchange (GHX), een leider op het gebied van cloud-based supply chain management oplossingen voor de gezondheidszorg, zal aanwezig zijn op de toonaangevende internationale vakbeurs voor de medische sector, MEDICA 2018, in Düsseldorf, Duitsland tussen 12 en 15 november 2018. GHX biedt een volledig assortiment van intelligente eCommerce en supply chain-oplossingen die specifiek ontworpen zijn voor de complexe wereld van de gezondheidszorg. De technol

 

MichBio To Present Inaugural Michigan Bioscience Pantheon Award to Ten Inductees at ExpoOpen in a New Window

ANN ARBOR, Mich.--(BUSINESS WIRE)--MichBio to Present Inaugural Michigan Bioscience Pantheon Awards to Ten Inductees at Expo

 

Nomination de M. Didier Leconte au conseil d'administration du CDRDOpen in a New Window

VANCOUVER, British Columbia--(BUSINESS WIRE)--CDRD – C’est avec plaisir que le Centre de recherche et développement des médicaments, la passerelle nationale pour les sciences de la vie au Canada, annonce la nomination de M. Didier Leconte au conseil d'administration de l’organisation. M. Leconte est Vice-président aux investissements, Sciences de la vie, au Fonds de solidarité FTQ, organisme auquel il s’est joint en 2012. Avec un actif net dépassant les 14 milliards de dollars, le Fonds de soli

 

CDRD Appoints Didier Leconte to Its Board of DirectorsOpen in a New Window

VANCOUVER, British Columbia--(BUSINESS WIRE)--#biotech--CDRD, Canada’s national life sciences venture, is pleased to announce the appointment of Mr. Didier Leconte as a new Director of the organization.

 

Ligand to Report Third Quarter 2018 Results on November 8thOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. Third Quarter 2018 Earnings Call What:       Ligand conference call to discuss financial results and provide general business updates   When: Thursday, November 8, 2018   Time: 9:00 a.m. East

 

Japan In Vitro Diagnostics (IVD) Market to 2024 By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Challenges, Opportunities - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Japan In Vitro Diagnostics (IVD) Market, By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Challenges, Opportunities" report has been added to ResearchAndMarkets.com's offering The Japanese In Vitro Diagnostics market is expected to surpass US$4.3 Billion by the end of year 2024 In Japan, In Vitro Diagnostics comes under medical devices, which are consumable or disposable and used to collect numerous bio-samples under various medical condit

 

European Laboratory Informatics (LIMS, ELN, LES, EDC, ECM, CDMS, SDMS) Market Forecast to 2024 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "European Laboratory Informatics Market By Product (LIMS, ELN, LES, EDC, ECM, CDMS, SDMS), Component (Services, Software), Delivery (On Premise, Cloud, Web), End User (Pharma, Biotech, MDx, Biobank, CRO, F&B, Oil, Gas, Chemical) - Forecast To 2024" report has been added to ResearchAndMarkets.com's offering. European Laboratory Informatics Market Worth $1,084.3 Million By 2024 Growing automation in laboratories, technological advancements in laboratory informatic

 

Global Personalized Medicine Market 2017-2024: Oncology is Estimated to Account for the Largest Market Segment Accounting for Approx 30% - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Personalized Medicine Market - Types, Technologies and Applications" report has been added to ResearchAndMarkets.com's offering. Global Personalized Medicine market is expected to witness a robust CAGR of over 11% during the 2017-2024 analysis period and projected to touch US$194.4 billion by 2024 from an estimated US$92.4 billion in 2017. By application, Oncology is estimated the largest market accounting for about 30% throughout the analysis period. Person

 

HiFiBiO Therapeutics Acquires H-Immune TherapeuticsOpen in a New Window

CAMBRIDGE, Mass. & PARIS & SHANGHAI--(BUSINESS WIRE)--HiFiBiO Therapeutics acquires H-Immune Therapeutics, an early-stage biotech company engaged in the development of novel immuno-oncology therapeutics

 

Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases ConferenceOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening

 

DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood TestOpen in a New Window

RICHMOND, Calif.--(BUSINESS WIRE)--DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection assays, announced today that it has received a $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to continue development of its RadToxTM cfDNA radiation therapy toxicity monitoring test kit for cancer patients. While radiation is required by 70 percent of cancer patients, there is currently no reliable me

 

Numenta Introduces Breakthrough Theory for Intelligence and Cortical ComputationOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)--#AI--Numenta researchers propose “The Thousand Brains Theory of Intelligence” - a broad framework for understanding how the neocortex works.

 

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic PatientsOpen in a New Window

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics announces initiation of phase 2 study with Regeneron and Sanofi of AR101 with adjunctive dupilumab in peanut-allergic patients.

 

Scientist.com’s Online Compliance Solution (COMPLi™) Wins Prestigious CPhl Pharma AwardOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--#fasterscience--Scientist.com is pleased to announce its online compliance solution COMPLi™ was recognized as the winner of the prestigious Regulatory Procedures and Compliance award at the 2018 CPhl Pharma Awards held in Madrid, Spain on October 9, 2018. COMPLi™ is a first-of-its-kind solution that allows pharmaceutical and biotech companies to confidently outsource regulated services such as human biological sample (HBS) acquisition, secondary real-world evidence (RWE), health eco

 

GHX präsentiert auf der MEDICA 2018 – Weltforum der MedizinOpen in a New Window

DÜSSELDORF--(BUSINESS WIRE)--Global Healthcare Exchange (GHX), ein führender Anbieter von cloudbasierten Supply-Chain-Management-Lösungen für das Gesundheitswesen, stellt auf der führenden Weltleitmesse der Medizinbranche MEDICA 2018 aus, die vom 12. bis 15. November 2018 in Düsseldorf stattfindet. GHX bietet ein umfassendes Angebot intelligenter E-Commerce- und Beschaffungslösungen, das speziell auf die Komplexität im Gesundheitswesen zugeschnitten ist. Die Technologie des Unternehmens verbind

 

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3Open in a New Window

PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead filed an application to begin a Phase 1 clinical trial of ARO-ANG3, RNAi-based investigational medicine for the treatment of dyslipidemias.

 

GHX expose au MEDICA 2018 – Forum Mondial de la MédecineOpen in a New Window

DÜSSELDORF, Allemagne--(BUSINESS WIRE)--Global Healthcare Exchange (GHX), un leader en solutions de gestion de la chaîne logistique de la santé basées sur le cloud, exposera à l'un des principaux salons internationaux du secteur médical, MEDICA 2018, qui aura lieu à Düsseldorf en Allemagne, du 12 au 15 novembre 2018. GHX propose une gamme complète de solutions intelligentes d'e-commerce et de gestion de la chaine logistique spécialement conçues pour le monde complexe des soins de santé. Grâce à

 

F-star Appoints Dr Eliot Forster as Chief Executive OfficerOpen in a New Window

CAMBRIDGE, England--(BUSINESS WIRE)--F-star, a clinical-stage biopharmaceutical company announced the appointment of Dr Eliot Forster as Chief Executive Officer.

 

Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual MeetingOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences today announced that it will be highlighting its Phase 1b/2 clinical data for AU-011 at the AAO 2018 Annual Meeting.

 

X4 Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for X4P-001-RD for the Treatment of WHIM SyndromeOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals has received Orphan Drug Designation from the U.S. FDA for X4P-001-RD for the treatment of WHIM syndrome.

 

X4 Pharmaceuticals and Collaborators Present Data that WHIM Syndrome is Underdiagnosed and Patients are Impacted by Broad Spectrum of Medical ComplicationsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals and collaborators present data that WHIM syndrome is under-diagnosed, has broad complications at NORD Rare Disease Summit.

 

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for GivosiranOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), rather than filing based on the inter

 

Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206Open in a New Window

PITTSBURGH & SAN JOSE, Calif.--(BUSINESS WIRE)--#PJI--Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206

 

Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New YorkOpen in a New Window

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #RettSyndrome--Newron Pharmaceuticals will host a research and development day featuring medical experts on schizophrenia and Rett syndrome on Oct. 31 in NYC.

 

NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged ProstateOpen in a New Window

WAYNE, Pa.--(BUSINESS WIRE)--NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift System Treatment for Enlarged Prostate

 

Resumen: Chugai lanza un anime de sensibilización para la artritis reumatoide en varios idiomas para enfatizar la importancia de la detección temprana y el tratamiento, así como el cuidado de los especialistasOpen in a New Window

TOKIO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKIO: 4519) ha anunciado el lanzamiento de un anime de sensibilización sobre la artritis reumatoide doblado en inglés y subtitulado en chino, coreano, francés y español, con motivo del Día mundial de la artritis, el 12 octubre. La artritis reumatoide es un trastorno autoinmunitario que afecta con mayor frecuencia a las mujeres de 30 a 59 años de edad. El número de pacientes se estima en 700.000 en Japón y 23 millones en el mundo*. La enf

 

Riassunto: Chugai presenta i risultati dello studio di fase III di satralizumab nel trattamento della NMOSD al congresso ECTRIMS 2018Open in a New Window

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha reso noto che i risultati dello studio di fase III di satralizumab (codice di sviluppo: SA237), Studio SAkuraSky (NCT02028884), sono stati presentati durante l’edizione 2018 del Congresso del Comitato europeo per il trattamento e la ricerca della sclerosi multipla (European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS), tenutosi a Berlino, in Germania, dal 10 al 12 ottobre. Il testo originale del pres

 

PharmSource - Cell Therapy Market Opportunity for CMOs: 2018 Edition - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition" report has been added to ResearchAndMarkets.com's offering. This report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity. Cell therapies represent an exciting and complex new treatment type, with the pot

 

Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. MarketOpen in a New Window

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). The Company is working towards la

 

中外製藥推出宣導類風濕性關節炎疾病知識的多種語言動畫片,強調早期檢測/專科治療和護理的重要性Open in a New Window

東京--(BUSINESS WIRE)--(美國商業資訊) -- 中外製藥株式會社(TOKYO:4519)今天宣佈推出有關類風濕性關節炎的疾病知識宣導動畫片,以迎接10月12日世界關節炎日,該動畫片有英文配音和中文、韓文、法文及西班牙文字幕。 類風濕性關節炎是自體免疫疾病,最常見於30至59歲的女性。日本和全球的病人數估計分別為70萬和2300萬*。該病導致關節和骨骼損害及手足變形,可嚴重影響日常生活。但隨著近來治療進步,只要及早在專科醫療中心就醫和接受適當治療,能夠控制關節腫脹疼痛、繼續家務及業餘愛好等日常活動的病人人數愈來愈多。*類風濕性關節炎和過敏反應研究委員會的報告; (http://www.mhlw.go.jp/stf/houdou/2r9852000001nfao-att/2r9852000001nfdx.pdf)和世界衛生組織全球疾病負擔報告(表7,第32頁)2004年; (http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf) 中外製藥一直強調類風濕性關節炎

 

QIAGEN N.V. to Report Third Quarter and First Nine Months of 2018 ResultsOpen in a New Window

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time (CET) / 16:00 Eastern Daylight Time (EDT). A conference call is planned for Tuesday, October 30 at 14:00 CET / 9:00 EDT hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. tim

 

NIH Awards Allele with Grant for the Development of Nanoantibody Therapies for Treating SepsisOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--$Cell #Ablynx--The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody (nAb) therapies for the treatment of sepsis. Sepsis and septic shock are among the leading causes of death in intensive care units (ICUs). The global incidence of sepsis has increased over the years, while the mortality rate, which can reach over 60% for septic shock, has

 

GHX Exhibiting at MEDICA 2018 – World Forum for HealthcareOpen in a New Window

DÜSSELDORF, Germany--(BUSINESS WIRE)--#EDI--Global Healthcare Exchange (GHX), exhibiting at leading international trade fair for the medical sector, MEDICA 2018, Düsseldorf, Germany 12-15 Nov

 

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressOpen in a New Window

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®). The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexil

 

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of SchizophreniaOpen in a New Window

BOSTON--(BUSINESS WIRE)--Karuna Announces Initiation of Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

 

Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant TreatmentOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (EBC) who have residu

 

Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, HyderabadOpen in a New Window

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed as

 

Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018Open in a New Window

TOKYO--(BUSINESS WIRE)--#NMOSD--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 held in Berlin, Germany from October 10 to 12. Satralizumab is a humanized investigational recycling anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum

 

Association Management Software Powered by YourMembership  ::  Legal